Richard Bryan Bell

8PUBLICATIONS
39CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer diagnosisCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 10, 2025
Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus-Initiated Oropharynx Cancer.

Barbara Burtness, Yael Flamand, Harry Quon

|Dec 26, 2023
FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment.

David A Knorr, Lucas Blanchard, Rom S Leidner

|Dec 17, 2021
Cancer case trends following the onset of the COVID-19 pandemic: A community-based observational study with extended follow-up.

Charles W Drescher, Adam J Bograd, Shu-Ching Chang

|Oct 26, 2021
Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).

Robert L Ferris, Yael Flamand, Gregory S Weinstein

|May 14, 2021
Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis.

Hongjun Li, Zejun Wang, Zhaowei Chen

|May 08, 2021
Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.

Rom Leidner, Marka Crittenden, Kristina Young

Pageof 2

Frequent Collaborators

3 joint publications

Rom S Leidner

2 joint publications

Neil D Gross

2 joint publications

Miriam N Lango

2 joint publications

Ranee Mehra